Publications

Date
Source
Title
June 22, 2022
FOCIS 2022
Induction of Antigen-Specific Immune Tolerance in Type 1 Diabetes by Antigen-Expressing Red Cell Therapeutics
May 17, 2022
ASCO 2022
A Phase 1/2 Study of RTX-224, an Engineered Red Blood Cell Expressing 4-1BB Ligand and Membrane-Bound IL-12, for the Treatment of Patients with Select Advanced Solid Tumors
April 8, 2022
AACR 2022
Phase 1 Trial of RTX-240, Allogeneic Red Blood Cells Engineered to Express 4-1BBL and Trans-Presented IL-15, in Patients with Advanced Solid Tumors
November 12, 2021
SITC 2021
RTX-224, An Engineered Allogeneic Red Cell Therapeutic Expressing 4-1BBL and IL-12, Activates Immune Cells in Blood and Spleen to Promote Tumor Growth Inhibition in Mice
July 12, 2021
Cancer Immunology, Immunotherapy
Anti-Tumor Effects of RTX-240: an Engineered Red Blood Cell Expressing 4-1BB Ligand and Interleukin-15
June 4, 2021
ASCO 2021
A Phase 1 Study of RTX-321, an Engineered Red Blood Cell as an Artificial Antigen-Presenting Cell Expressing HLA-A*02 with the HPV-16 E7 Peptide and 4-1BB Ligand with Membrane-Bound IL-12 for the Treatment of HPV 16-Positive Cancers
May 12, 2021
Nature Communications
Engineered Red Blood Cells as an Off-the-Shelf Allogeneic Anti-Tumor Therapeutic
April 10, 2021
AACR 2021
A Phase 1 Trial of RTX-240, an Allogeneic Engineered Red Blood Cell With Cell-Surface Expression of 4-1BBL and Trans-Presented IL-15, in Patients With Advanced Solid Tumors
November 9, 2020
SITC 2020
RTX-240, an Allogeneic Engineered Red Blood Cell Expressing 4-1BBL and IL-15TP, Promotes NK Cell Functionality In Vitro and In Vivo
October 28, 2020
FOCIS 2020
An Engineered Allogeneic Artificial Antigen-Presenting Red Cell Therapeutic™, RTX-321, Promotes Antigen-Specific T Cell Expansion and Anti-Tumor Activity
October 19, 2020
AACR Tumor Immunology and Immunotherapy 2020
RTX-321, an Allogeneic Red Blood Cell-Based Artificial Antigen-Presenting Cell, Expressing MHC I Peptide, 4-1BBL, and IL-12, Engages Primary Human HPV-Specific T Cells, and Boosts Other General Immune Responses
June 22, 2020
AACR 2020
In Vivo Efficacy and Pharmacodynamic Analysis of RTX-321, an Engineered Allogeneic Artificial Antigen Presenting Red Cell Therapeutic
April 30, 2020
ASGCT 2020
An Engineered Allogeneic Artificial Antigen-Presenting Red Cell Therapeutic, RTX-321, for HPV16+ Associated Cancers Promotes Antigen-Specific T Cell Activation and Expansion
April 30, 2020
ASGCT 2020
Engineered Red Cell Therapeutics as Artificial Antigen Presenting Cells Promote in vitro Expansion of both Naïve and Exhausted CD4+ T Cells
February 7, 2020
Keystone Symposia 2020 - Emerging Cellular Therapies: Cancer and Beyond
An Engineered Allogeneic Artificial Antigen-Presenting Red Cell Therapeutic, RTX-321, Promotes Antigen-Specific T Cell Expansion and Anti-Tumor Activity
November 6, 2019
SITC 2019
RTX-321, an Allogeneic Artificial Antigen Presenting Cell (aAPC) Red Cell Therapeutic, Expressing MHC I-Peptide, 4-1BBL and IL-12, Promotes Expansion and Anti-Tumor Activity of Antigen-Specific T Cells in HPV16-Positive Tumors
October 24, 2019
AACR-NCI-EORTC 2019
Enabling the Rapid Generation of Allogeneic Artificial Antigen Presenting Cell (aAPC) Red Cell Therapeutics with a Loadable MHC System
July 10, 2019
RNA Therapeutics Conference 2019
mRNA-based Engineering of Red Cell Therapeutics (RCTs) to Generate Potent, Allogeneic Cellular Therapies
March 7, 2019
AACR 2019
RTX-240, an Allogeneic Red Cell Therapeutic Expressing 4-1BBL and IL-15TP, Exhibits Potent In Vitro and In Vivo Activity and a Favorable Safety Profile
March 7, 2019
AACR 2019
RTX-224, an Allogeneic Red Cell Therapeutic Expressing IL-12 and 4-1BBL, Exhibits Potent In Vitro and In Vivo Activity and a Favorable Safety Profile
March 5, 2019
AACR 2019
Engineered Red Cell Therapeutics (RCT) as Artificial Antigen Presenting Cells Promote and Antitumor Activity of Antigen Specific T Cells